What’s In A Name? Janssen’s Loss Of Sovriad Was Gilead’s Gain With Sovaldi
This article was originally published in Pharmaceutical Approvals Monthly
FDA initially rejected both sponsors’ preferred proprietary names for their hepatitis C treatments due to the risk of confusion with each other. Janssen had to settle for Olysio, its backup name for simeprevir, leaving Gilead to claim title to its preferred name for sofosbuvir.